Omecamtiv Mecarbil in Systolic Heart Failure. Reply

Affiliations

¹ University of California San Francisco School of Medicine, San Francisco, CA john.teerlink@ucsf.edu.
² Duke University School of Medicine, Durham, NC.
³ University of Glasgow, Glasgow, United Kingdom.

Comment

John R Teerlink et al. N Engl J Med. 2021.

. 2021 May 20;384(20):1967-1968.

doi: 10.1056/NEJMc2102893.

¹ University of California San Francisco School of Medicine, San Francisco, CA john.teerlink@ucsf.edu.
² Duke University School of Medicine, Durham, NC.
³ University of Glasgow, Glasgow, United Kingdom.

No abstract available

Comment on

Omecamtiv Mecarbil in Systolic Heart Failure.
Komamura K. Komamura K. N Engl J Med. 2021 May 20;384(20):1966-1967. doi: 10.1056/NEJMc2102893. N Engl J Med. 2021. PMID: 34010538 No abstract available.
Omecamtiv Mecarbil in Systolic Heart Failure.
Bonapace S, Molon G. Bonapace S, et al. N Engl J Med. 2021 May 20;384(20):1967. doi: 10.1056/NEJMc2102893. N Engl J Med. 2021. PMID: 34010539 No abstract available.
Omecamtiv Mecarbil in Systolic Heart Failure.
Bellumkonda L. Bellumkonda L. N Engl J Med. 2021 May 20;384(20):1967. doi: 10.1056/NEJMc2102893. N Engl J Med. 2021. PMID: 34010540 No abstract available.